Another of today's winners in the health-care space is Myriad Genetics (NASDAQ:MYGN), up 11% today after Medicare reimbursement cuts were announced. Though the cuts were harsh, they were lower than the market had been fearing, and Myriad came out on top as a result.
In this video, Motley Fool health-care analyst David Williamson discusses the Medicare cuts and the fact that they were still extremely severe, despite not being as severe as once feared. He also gives investors a few reasons not to love Myriad Genetics, despite the boost it got today from the market's expectations game.
Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and it's ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.